Abstract: Objective The aim of this study was to investigate clinical efficacy of endoscopic variceal ligation (EVL) and somatostatin and esomeprazole combination in the treatment of patients with liver cirrhosis (LC) with complicated esophagogastric variceal bleeding(EVB). Methods Consecutive 77 patients with LC and complicated EVB were encountered in our hospital between April 2022 and April 2024, and were randomly divided into control (n=38) and observation (n=39) group, receiving intravenous infusion of somatostatin and esomeprazole, or receiving EVL plus intravenous infusion of the two medicines. Portal vein diameter (Dpv), portal vein blood flow velocity (Vpv) and portal vein blood flow volume (Qpv) were detected by Doppler ultrasonography. Results For hemostasis, blood transfusion, bleeding-stopping time, supplemented albumin and hospital stay in the observation group were (240.3±131.4)mL,(3.7±0.5)h,(10.4±2.9)g and (5.7±0.8)d, all much less or shorter than [(596.2±238.9)mL, (44.3±4.1)h, (44.2±12.5)g and (11.6±1.4)d, respectively, P<0.05]in the control; 14 days after treatment, Vpv and Qpv in the observation were (15.8±2.2)cm/s and (944.2±245.5)mL/min, both significantly faster or greater than [(13.4±2.3)cm/s and (776.7±170.6)mL/min, respectively, P<0.05] in the control; serum fibrinogen level was(2.9±0.5)g/L, much higher than [(2.2±0.6)g/L, P<0.05] in the control; the emergent hemostasis rate in the observation was 97.4%, much higher than 84.2%(P<0.05)in the control; by end of six month follow-up, re-bleeding rate was 2.6% and esophagogastric varices relapse was 7.9%, both much lower than 18.8% and 25.0%(P<0.05)in the control group. Conclusion EVL at base of intravenous infusion of somatostatin and esomeprazole in the treatment of patients with LC and EVB is efficacious with high emergent hemostasis, and less rebleeding and low EV relapse.

Key words: Liver cirrhosis, Esophagogastric variceal bleeding, Endoscopic variceal ligation, Somatostatin, Esomeprazole, Therapy